Effectiveness and cost-effectiveness of pediatric rotavirus vaccination in British Columbia: A model-based evaluation

Vaccine

Volumn 30, Issue 52, 2012, Pages 7601-7607

  Fisman, David N ^a   Chan, Christina H ^a   Lowcock, Elizabeth ^a,b   Naus, Monika ^c,e   Lee, Victoria ^a,c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b CANCER CARE ONTARIO   (Canada)

^c BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^d Fraser Health Authority   (United Kingdom)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cost effectiveness; Health economics; Immunization; Mathematical modeling; Rotavirus

Indexed keywords

ROTAVIRUS VACCINE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; IMMUNIZATION; MONTE CARLO METHOD; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; ROTAVIRUS INFECTION; SENSITIVITY ANALYSIS; VACCINATION;

BRITISH COLUMBIA; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; GASTROENTERITIS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MODELS, STATISTICAL; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINATION;

EID: 84870568108     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.10.034     Document Type: Article

References (38)

1. World Health Organization. Decision making and implementation of rotavirus vaccines: Vaccine utilization. 2009 [cited 2009 December 10]; Available from: http://www.who.int/nuvi/rotavirus/decision_implementation/en/index1.html.
2. Parashar U.D., Burton A., Lanata C., Boschi-Pinto C., Shibuya K., Steele D., et al. Global mortality associated with rotavirus disease among children in 2004. J Infect Dis 2009, 200(November (Suppl. 1)):S9-S15.
3. National Advisory Committee on Immunization (NACI) Statement on the recommended use of pentavalent human-bovine reassortant rotavirus vaccine. An Advisory Committee Statement (ACS). Can Commun Dis Rep 2008, 34(January (ACS-1)):1-33.
4. World Health Organization Meeting of the immunization Strategic Advisory Group of Experts. April 2009 - conclusions and recommendations. Wkly Epidemiol Rec 2009, 23(June):220-236.
5. Danchin M.H., Bines J.E. Defeating rotavirus? The global recommendation for rotavirus vaccination. N Engl J Med. 2009, 361(November (20)):1919-1921.
6. Kudjawu Y., Levy-Bruhl D., Celentano L.P., O'Flanagan D., Salmaso S., Lopalco P., et al. The current status of HPV and rotavirus vaccines in national immunisation schedules in the EU-preliminary results of a VENICE survey. Euro Surveill 2007, 12(April (4)). E070426 1.
7. Nohynek H., Salo H., Renko M., Leino T. Finland introduces rotavirus vaccine into the national vaccination programme in September 2009. Euro Surveill 2009, 14(35). http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19322.
8. Widdowson M.A., Steele D., Vojdani J., Wecker J., Parashar U. Global rotavirus surveillance: determining the need and measuring the impact of rotavirus vaccines. J Infect Dis 2009, 200(S1):S1-S8.
9. National Advisory Committee on Immunization (NACI) Updated statement on the use of rotavirus vaccines. An Advisory Committee Statement (ACS). Can Commun Dis Rep 2010, 36(July (ACS-4)):1-37.
10. Erickson L.J., De Wals P., Farand L. An analytical framework for immunization programs in Canada. Vaccine 2005, 23(March (19)):2470-2476.
11. Mangen M.J., van Duynhoven Y.T., Vennema H., van Pelt W., Havelaar A.H., de Melker H.E. Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program?. Vaccine 2010, 28(March (14)):2624-2635.
12. Brisson M., Edmunds W.J. Economic evaluation of vaccination programs: the impact of herd-immunity. Med Decision Making 2003, 23(January-February (1)):76-82.
13. Anderson R.M., May R.M. Infectious Diseases of Humans: Dynamics and Control 1991, Oxford University Press, Oxford, UK.
14. Brisson M., Edmunds W.J. Varicella vaccination in England and Wales: cost-utility analysis. Arch Dis Child 2003, 88(October (10)):862-869.
15. The burden of rotavirus-associated gastroenteritis in young Canadian children: A cohort model, 97th Canadian Public Health Association Meeting 2006 2006, M. Sénécal, C. Quach, M. Brisson (Eds.).
16. Ruiz-Palacios G.M., Perez-Schael I., Velazquez F.R., Abate H., Breuer T., Clemens S.C., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354(January (1)):11-22.
17. Vesikari T., Karvonen A., Prymula R., Schuster V., Tejedor J.C., Cohen R., et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007, 370(November (9601)):1757-1763.
18. Vesikari T., Matson D.O., Dennehy P., Van Damme P., Santosham M., Rodriguez Z., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006, 354(January (1)):23-33.
19. Zhou W., Pool V., Iskander J.K., English-Bullard R., Ball R., Wise R.P., et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)-United States, 1991-2001. MMWR Surveill Summ 2003, 52(January (1)):1-24.
20. Birch S., Gafni A., O'Brien B. Willingness to pay and the valuation of programmes for the prevention and control of influenza. Pharmacoeconomics 1999, 16(Suppl. 1):55-61.
21. Brisson M., Senecal M., Drolet M., Mansi J.A. Health-related quality of life lost to rotavirus-associated gastroenteritis in children and their parents: a Canadian prospective study. Pediatr Infect Dis J 2010, 29(January (1)):73-75.
22. Senecal M., Brisson M., Lebel M.H., Yaremko J., Wong R., Gallant L.A., et al. Measuring the impact of rotavirus acute gastroenteritis episodes (MIRAGE): a prospective community-based study. Can J Infect Dis Med Microbiol 2008, 19(November (6)):397-404.
23. Milne R.J., Grimwood K. Budget impact and cost-effectiveness of including a pentavalent rotavirus vaccine in the New Zealand childhood immunization schedule. Value Health 2009, 12(September (6)):888-898.
24. Consumer Price Index, health and personal care, by province. Government of Canada. Available via the Internet at; 2011 [last accessed 31.03.11] [database on the Internet]. http://www40.statcan.ca/l01/cst01/econ161a-eng.htm.
25. Weinstein M.C., Siegel J.E., Gold M.R., Kamlet M.S., Russell L.B. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996, 276(October (15)):1253-1258.
26. Kim J.J., Kuntz K.M., Stout N.K., Mahmud S., Villa L.L., Franco E.L., et al. Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol 2007, 166(July (2)):137-150.
27. Ford-Jones E.L., Wang E., Petric M., Corey P., Moineddin R., Fearon M. Hospitalization for community-acquired, rotavirus-associated diarrhea: a prospective, longitudinal, population-based study during the seasonal outbreak. The Greater Toronto Area/Peel Region PRESI Study Group. Pediatric rotavirus epidemiology study for immunization. Arch Pediatr Adolesc Med 2000, 154(June (6)):578-585.
28. Rivest P., Proulx M., Lonergan G., Lebel M.H., Bedard L. Hospitalisations for gastroenteritis: the role of rotavirus. Vaccine 2004, 22(May (15-16)):2013-2017.
29. ACIP Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2009, 48(March (RR-2)):1-20.
30. Payne D.C., Staat M.A., Edwards K.M., Szilagyi P.G., Gentsch J.R., Stockman L.J., et al. Active, population-based surveillance for severe rotavirus gastroenteritis in children in the United States. Pediatrics 2008, 122(December (6)):1235-1243.
31. Briggs A. Handling uncertainty in economic evaluation. Economic evaluation in health care: merging theory with practice 2001, 172-204. Oxford University Press, Oxford, UK. 1st ed. M. Drummond, A. McGuire (Eds.).
32. Bilcke J., Beutels P. Reviewing the cost effectiveness of rotavirus vaccination: the importance of uncertainty in the choice of data sources. Pharmacoeconomics 2009, 27(4):281-297.
33. Kim S.Y., Sweet S., Slichter D., Goldie S.J. Health and economic impact of rotavirus vaccination in GAVI-eligible countries. BMC Public Health 2010, 10:253.
34. Fisman D.N., Mittleman M.A., Sorock G.S., Harris A.D. Willingness to pay to avoid sharps-related injuries: a study in injured health care workers. Am J Infect Control 2002, 30(August (5)):283-287.
35. Gold M.R., Stevenson D., Fryback D.G. HALYS and QALYS and DALYS, Oh My: similarities and differences in summary measures of population health. Annu Rev Public Health 2002, 23:115-134.
36. O'Brien B., Gafni A. When do the "dollars" make sense? Toward a conceptual framework for contingent valuation studies in health care. Med Decis Making 1996, 16(July-September (3)):288-299.
37. Velázquez F.R., Matson D.O., Calva J.J., Guerrero M.L., Morrow A.L., Carter-Campbell S., et al. Rotavirus infection in infants as protection against subsequent infections. New Engl J Med 1996, 335(14):1022-1028.
38. British Columbia Ministry of Health. In: Health Mo, editor. British Columbia Medical Services Plan billing schedule. Victoria, BC: Province of British Columbia; Available via the Internet at; 2011 [last accessed 31.03.11]. http://www.health.gov.bc.ca/msp/infoprac/physbilling/payschedule/pdf/.